Vigil Neuroscience (VIGL)

• Market cap: $74.7M
• 1 day: 7.38%
• 5 days: -0.62%
• 1 month: -20.79%
• 3 months: -10.11%
• 6 months: -55.31%
• Year to date: -9.60%
• 1 year: -49.37%
• 5 years: -87.35%
• 10 years: -87.35%
• Sector: Healthcare
• Industry: Biotechnology

About: Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.

Employees: 69

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

73% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 11

9% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 11

0% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]

2% less funds holding

Funds holding: 52 [Q3] → 51 (-1) [Q4]

14.61% less ownership

Funds ownership: 69.92% [Q3] → 55.32% (-14.61%) [Q4]

59% less capital invested

Capital invested by funds: $94.5M [Q3] → $38.4M (-$56M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $13 713% upside
• Avg. target: $13.50 744% upside
• High target: $14 775% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Wedbush Laura Chico 6% 1-year accuracy 3 / 50 met price target	713% upside $13	Outperform Maintained	14 Mar 2025
HC Wainwright & Co. Andrew Fein 24% 1-year accuracy 85 / 354 met price target	775% upside $14	Buy Maintained	14 Mar 2025